DZ Bank
GTHX

DZ Bank’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

DZ Bank’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,253
Closed -$83K – 1113
2018
Q1 		$83K Buy
+2,253
New +$60.1K ﹤0.01% 1022

Other funds holding GTHX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

DZ Bank's GTHX Position: Q2 2018 in Review

DZ Bank sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2018, closing a stake of 2,253 shares — an estimated $83K sold.

DZ Bank first reported a position in GTHX in Q1 2018 and held it in 1 quarter. The position peaked at $83K in Q1 2018. 95 funds tracked by Wall St. Rank hold GTHX as of Q2 2018.

  • DZ Bank reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • DZ Bank sold 2,253 G1 Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $83K.
  • DZ Bank first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
  • DZ Bank's G1 Therapeutics, Inc. Common Stock position peaked at $83K in Q1 2018.
  • 95 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2018.

Based on DZ Bank's 13F filing for Q2 2018, filed 14 Aug 2018.